Betnovate
In stock
0,1%
from 2,24 £
In brief
Inflamed, itchy skin may respond to betamethasone valerate, a potent topical corticosteroid. It suppresses local inflammation in conditions such as eczema, with the site and duration of treatment affecting suitability.
How Betnovate works in your body
Betnovate operates by penetrating the skin and binding to glucocorticoid receptors inside cells. This action suppresses inflammatory chemicals like prostaglandins and leukotrienes, rapidly reducing redness, swelling, and itching. Its potent anti-inflammatory effects make it effective for various skin conditions.
| Interacting substance | Risk | Precaution |
|---|---|---|
| Azole antifungals | Systemic absorption increased | Avoid concurrent use without medical guidance |
| Rifampicin | Reduced effectiveness | Monitor treatment response |
After application, most betamethasone remains near skin surfaces, with only a small proportion absorbed systemically. It's metabolised primarily through CYP3A4 liver pathways before kidney excretion. Continuous use beyond recommended durations or on large skin areas risks absorption levels that may affect cortisol production, particularly in vulnerable groups.
Conditions Betnovate treats
MHRA-approved uses
The Medicines and Healthcare products Regulatory Agency (MHRA) authorises Betnovate for specific inflammatory conditions. The strongest evidence supports its use for:
- Eczema/dermatitis: Proven relief for flare-ups
- Psoriasis: Effective for stable plaque psoriasis
- Lichen planus: Reduces characteristic purple lesions
Off-label applications
Specialists sometimes prescribe betamethasone valerate beyond official indications. Such off-label use may include:
Severe contact dermatitis – Where weaker steroids failed
Localised neurodermatitis – Under careful monitoring
Alopecia areata – As part of combination therapy
Localised neurodermatitis – Under careful monitoring
Alopecia areata – As part of combination therapy
Betnovate isn't suitable for children under age 1 and requires pregnancy consideration. The NHS advises against routine use during pregnancy – only doctors should determine if benefits outweigh potential risks.
Recommended dosages for specific skin problems
| Condition | Application | Maximum duration |
|---|---|---|
| Eczema/dermatitis | Thin film twice daily | 2 weeks |
| Psoriasis plaques | Once daily to affected areas | 4 weeks |
| Lichen planus | Twice daily (non-facial) | 3 weeks |
| Resistant dermatitis* | Occlusive dressing medical supervision only | 1 week |
*Off-label usage requiring doctor consultation
Apply sparingly – one fingertip unit (about 0.5g) covers an area twice your palm size. For elderly patients or thin-skinned areas, practitioners often reduce frequency due to heightened skin atrophy risk. Treatment longer than four weeks requires periodic medical reviews and gradual tapering. For example: transition to once-daily applications for the final week before stopping to prevent steroid withdrawal reactions.
Administration and storage best practices
Apply Betnovate to clean, dry skin using the smallest effective amount - a thin layer covering the affected area usually suffices. Wash hands before and after application, unless treating hands specifically. For missed doses, apply as soon as remembered unless near the next scheduled dose. Never double the dose to compensate.
The tube opening should never contact skin to prevent contamination. Replace caps firmly after each use. Store Betnovate tubes below 25°C, away from direct sunlight or freezing conditions. During travel, keep in original packaging protected from temperature extremes.
| Formulation | Application tip | Duration limit |
|---|---|---|
| Cream | Smooth gently until absorbed | Maximum 4 weeks |
| Ointment | Apply sparingly onto dry patches | Maximum 4 weeks |
| Scalp lotion | Part hair before applying | Maximum 2 weeks |
Contraindications and precautions
Betnovate must not be used for:
• Active fungal, viral or untreated bacterial infections
• Rosacea or perioral dermatitis
• Tubercular skin lesions
• Hypersensitivity reactions
• Active fungal, viral or untreated bacterial infections
• Rosacea or perioral dermatitis
• Tubercular skin lesions
• Hypersensitivity reactions
Special precautions apply for:
• Facial/genital application due to enhanced absorption
• Children under age 1
• Large-area treatments (>10% body surface)
• Pregnancy requires specialist supervision
• Hepatic impairment patients need monitoring
• Facial/genital application due to enhanced absorption
• Children under age 1
• Large-area treatments (>10% body surface)
• Pregnancy requires specialist supervision
• Hepatic impairment patients need monitoring
Discontinue immediately if these develop:
- Worsening redness/itching
- Pus formation
- Sudden skin thinning
- Visual disturbances
- Worsening redness/itching
- Pus formation
- Sudden skin thinning
- Visual disturbances
Side effects profile
Most Betnovate reactions occur at application sites:
• Burning/stinging (common initially)
• Dryness and skin peeling (frequent)
• Itching exacerbation (occasional)
• Burning/stinging (common initially)
• Dryness and skin peeling (frequent)
• Itching exacerbation (occasional)
Prolonged use risks:
• Skin atrophy and striae (stretch marks)
• Telangiectasia (broken capillaries)
• Folliculitis/hypertrichosis
• Hypopigmentation
• Systemic HPA-axis suppression with large-area treatment
• Skin atrophy and striae (stretch marks)
• Telangiectasia (broken capillaries)
• Folliculitis/hypertrichosis
• Hypopigmentation
• Systemic HPA-axis suppression with large-area treatment
| Side effect | Frequency | Typical severity |
|---|---|---|
| Transient stinging | Common (1 in 10) | Mild |
| Contact dermatitis | Occasional (1 in 100) | Moderate |
| Skin atrophy | Rare ( | Severe |
| HPA suppression | Very rare | Serious |
Therapeutic alternatives to Betnovate: UK comparison
When Betnovate proves unsuitable, clinicians consider corticosteroid alternatives across potency tiers. Dermovate (clobetasol propionate) ranks highest with ultra-high potency for severe plaques but carries greater skin atrophy risks. Elocon (mometasone furoate) offers comparable efficacy to Betnovate for eczema with marginally lower systemic absorption. Mild conditions warrant hydrocortisone 1%, though its weaker action may extend treatment durations.
| Alternatives | Relative potency | Safety profile |
|---|---|---|
| Dermovate (clobetasol) | Very potent | Higher risk monitoring |
| Elocon (mometasone) | Potent (similar) | Medium vigilance |
| Hydrocortisone 1% | Mild | Lower risk |
Betnovate is a prescription-only medicine, whereas hydrocortisone 1% cream is available from pharmacies without a prescription for limited use on small areas.
